ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

1:30PM-1:45PM: Abstract Number: 1658

Cardiovascular Disease Risk and Risk Calculator Performance in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Abstracts: Health Services Research (1656–1661)

1:30PM-1:45PM: Abstract Number: 1670

Large Retrospective Cohort Study Of Chronic Recurrent Multifocal Osteomyelitis: Disease Presentation, Clinical, And Laboratory Features

Abstracts: Pediatric Rheumatology – Clinical I (1668–1673)

1:30PM-1:45PM: Abstract Number: 1676

Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study

Abstracts: Rheumatoid Arthritis – Treatment I: Preventative and Novel Treatments (1674–1679)

1:30PM-1:45PM: Abstract Number: 1682

Sjögren’s Disease Salivary Gland Fibroblast Subsets are Proinflammatory and Aberrantly Promote Pain

Abstracts: Sjögren’s Disease – Basic & Clinical Science (1680–1685)

1:30PM-1:45PM: Abstract Number: 1652

The Hidden Impact of Hyperuricemia on Immune Cell Dysfunction

Abstracts: Cytokines & Cell Trafficking (1650–1655)

1:45PM-2:00PM: Abstract Number: 1665

Comparative Effectiveness of Biologic Versus Conventional Therapy in Uveitis with Systemic Rheumatic Diseases: Real-World Evidence from a Propensity-Matched Cohort

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II: Models and Mechanisms (1662–1667)

1:45PM-2:00PM: Abstract Number: 1671

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Abstracts: Pediatric Rheumatology – Clinical I (1668–1673)

1:45PM-2:00PM: Abstract Number: 1677

First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care

Abstracts: Rheumatoid Arthritis – Treatment I: Preventative and Novel Treatments (1674–1679)

1:45PM-2:00PM: Abstract Number: 1653

Gut-joint lymphocyte trafficking functions to regulate systemic immunity

Abstracts: Cytokines & Cell Trafficking (1650–1655)

1:45PM-2:00PM: Abstract Number: 1659

Prevalence and Progression of Multimorbidity in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Abstracts: Health Services Research (1656–1661)

1:45PM-2:00PM: Abstract Number: 1683

Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort

Abstracts: Sjögren’s Disease – Basic & Clinical Science (1680–1685)

2:00PM-2:15PM: Abstract Number: 1654

A Dual Inhibitor of TAK1 and MAP4K2, NG25, Suppresses Cytokine-Driven Inflammation in Juvenile Idiopathic Arthritis Synovial Fibroblasts

Abstracts: Cytokines & Cell Trafficking (1650–1655)

2:00PM-2:15PM: Abstract Number: 1678

Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study

Abstracts: Rheumatoid Arthritis – Treatment I: Preventative and Novel Treatments (1674–1679)

2:00PM-2:15PM: Abstract Number: 1672

Classification criteria, disease phenotypes and long-term outcomes of childhood Sjögren’s Disease into adulthood

Abstracts: Pediatric Rheumatology – Clinical I (1668–1673)

2:00PM-2:15PM: Abstract Number: 1660

Digital Psychological Support for Inflammatory Rheumatic Diseases: A Randomized Clinical Trial

Abstracts: Health Services Research (1656–1661)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].